---
title: "AIM ImmunoTech Inc. (AIM.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/AIM.US/overview.md"
symbol: "AIM.US"
name: "AIM ImmunoTech Inc."
parent: "https://longbridge.com/zh-HK/quote/AIM.US.md"
datetime: "2026-04-15T18:58:39.123Z"
locales:
  - [en](https://longbridge.com/en/quote/AIM.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AIM.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AIM.US/overview.md)
---

# AIM ImmunoTech Inc. (AIM.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | 生物技術 |
| 交易所 | US Market |
| 地址 | 2117 SW Highway 484, Ocala, Florida, United States |
| 官網 | [aimimmuno.com](https://aimimmuno.com) |

## 公司簡介

AIM ImmunoTech Inc.是一家免疫藥物公司，專注于在美國研發治療多種癌症、病毒性疾病和免疫缺陷疾病的療法。其旗艦產品為 Ampligen（rintatolimod），這是一種用于治療慢性疲勞綜合症的大分子雙鏈核糖核酸藥物；以及 Alferon N Injection（幹擾素α），這是一種純化的天然來源的糖基化多物種α幹擾素產品，用于治療生殖器疣。該公司還在開發 Ampligen，以期用于治療胰腺癌、腎細胞癌、惡性黑色素瘤、非小細胞肺癌、卵巢癌、乳腺癌、結直腸癌和前列腺癌，以及用于治療肌痛性腦脊髓炎、乙型肝炎、HIV、COVID-19 和后 COVID 症狀。該公司曾被稱為 Hemispherx Biopharma, Inc

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Thomas K. Equels | Executive Vice Chairman, CEO & President |
| William M. Mitchell | Independent Chairman of the Board & Member of Scientific Advisory Board |
| Robert Dickey | Chief Financial Officer |
| Peter W. Rodino | COO, Executive Director of Governmental Relations, General Counsel & Secretary |
| Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator |
| Christopher Nicodemus | Member of Scientific Advisory Board & Consulting Science Officer |
| W. Neal Burnette | Chairman of Scientific Advisory Board |
| Nancy K. Bryan | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| DRW Holdings, LLC | 0.85% | 2025-12-31 |
| Thomas K. Equels | 0.78% | 2026-03-12 |
| Ted Douglas Kellner | 0.46% | 2025-10-24 |
| Armistice Capital LLC | 0.41% | 2024-12-31 |
| David I. Chemerow | 0.35% | 2026-03-12 |
| The Vanguard Group, Inc. | 0.22% | 2025-12-31 |
| Geode Capital Management, LLC | 0.21% | 2025-12-31 |
| Todd A. Deutsch | 0.21% | 2024-12-19 |
| William M. Mitchell | 0.06% | 2025-10-24 |
| Peter W. Rodino | 0.05% | 2025-10-24 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| 基于自然免疫系統的新藥治療的臨床開發 | 88000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "AIM ImmunoTech Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "基于自然免疫系統的新藥治療的臨床開發",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| 美國 | 88000 | 100% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**